Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER.

Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.

PMID:
30951193
2.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

3.

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.

Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.

Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018.

4.

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.

Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM.

JAMA Oncol. 2018 Nov 1;4(11):1535-1542. doi: 10.1001/jamaoncol.2018.3542.

5.

Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.

González JM, Doan J, Gebben DJ, Boeri M, Fishman M.

Pharmacoeconomics. 2018 Aug;36(8):973-986. doi: 10.1007/s40273-018-0640-7.

PMID:
29869777
6.

Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience.

Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ.

Clin Genitourin Cancer. 2018 Oct;16(5):e1003-e1013. doi: 10.1016/j.clgc.2018.05.012. Epub 2018 May 18.

PMID:
29859736
7.

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, Choueiri TK.

Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10.

PMID:
29439857
8.

Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive.

Fishman MN.

Transl Androl Urol. 2017 Oct;6(5):839-847. doi: 10.21037/tau.2017.08.02. Review.

9.

Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia.

Gonzalez BD, Small BJ, Cases MG, Williams NL, Fishman MN, Jacobsen PB, Jim HSL.

Cancer. 2018 Feb 1;124(3):499-506. doi: 10.1002/cncr.31024. Epub 2017 Oct 26.

10.

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.

Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr.

Cancer. 2017 Dec 1;123(23):4566-4573. doi: 10.1002/cncr.30942. Epub 2017 Aug 22.

11.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

12.

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2017 Jun;15(6):804-834. doi: 10.6004/jnccn.2017.0100.

PMID:
28596261
13.

Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison.

Donovan KA, Gonzalez BD, Nelson AM, Fishman MN, Zachariah B, Jacobsen PB.

Psychooncology. 2018 Jan;27(1):316-324. doi: 10.1002/pon.4463. Epub 2017 Jun 27.

14.

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.

Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE.

Target Oncol. 2017 Jun;12(3):333-340. doi: 10.1007/s11523-017-0487-4.

PMID:
28361451
15.

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma.

Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R.

J Vasc Interv Radiol. 2017 Feb;28(2):254-259. doi: 10.1016/j.jvir.2016.09.025. Epub 2016 Dec 7.

PMID:
27955832
16.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

17.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M.

Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. Epub 2016 May 11.

18.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

19.

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.

Rini BI, Tomita Y, Melichar B, Ueda T, Grünwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E.

Clin Genitourin Cancer. 2016 Dec;14(6):499-503. doi: 10.1016/j.clgc.2016.04.005. Epub 2016 Apr 22.

PMID:
27236772
20.

Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.

Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB.

Clin Cancer Res. 2016 Nov 15;22(22):5605-5616. doi: 10.1158/1078-0432.CCR-15-1673. Epub 2016 May 24.

21.

Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Nelson AM, Gonzalez BD, Jim HS, Cessna JM, Sutton SK, Small BJ, Fishman MN, Zachariah B, Jacobsen PB.

Support Care Cancer. 2016 Oct;24(10):4159-66. doi: 10.1007/s00520-016-3241-z. Epub 2016 May 3.

22.

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.

Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ.

World J Urol. 2016 Nov;34(11):1567-1573. Epub 2016 Apr 12.

PMID:
27072536
23.

Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions.

Poleszczuk JT, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, Djeu JY, Finkelstein SE, Enderling H.

Cancer Res. 2016 Mar 1;76(5):1009-18. doi: 10.1158/0008-5472.CAN-15-1423. Epub 2016 Feb 1.

24.

Evaluation of the psychometric properties of the PROMIS Cancer Fatigue Short Form with cancer patients.

Cessna JM, Jim HS, Sutton SK, Asvat Y, Small BJ, Salsman JM, Zachariah B, Fishman M, Field T, Fernandez H, Perez L, Jacobsen PB.

J Psychosom Res. 2016 Feb;81:9-13. doi: 10.1016/j.jpsychores.2015.12.002. Epub 2015 Dec 11.

25.

Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Gonzalez BD, Jim HSL, Small BJ, Sutton SK, Fishman MN, Zachariah B, Heysek RV, Jacobsen PB.

Support Care Cancer. 2016 May;24(5):2201-2207. doi: 10.1007/s00520-015-3016-y. Epub 2015 Nov 13.

26.

Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.

Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M.

Urol Oncol. 2016 Mar;34(3):122.e1-7. doi: 10.1016/j.urolonc.2015.09.015. Epub 2015 Nov 3.

27.

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma.

Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM.

Can J Urol. 2015 Aug;22(4):7882-9.

PMID:
26267026
28.

Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE.

Urol Oncol. 2015 Aug;33(8):339.e17-23. doi: 10.1016/j.urolonc.2015.01.011. Epub 2015 Jun 18.

PMID:
26094169
29.

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, Park JY, Spiess PE, Fishman MN, Jacobsen PB.

J Clin Oncol. 2015 Jun 20;33(18):2021-7. doi: 10.1200/JCO.2014.60.1963. Epub 2015 May 11.

30.

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.

Fishman MN, Tomshine J, Fulp WJ, Foreman PK.

PLoS One. 2015 Apr 1;10(4):e0120877. doi: 10.1371/journal.pone.0120877. eCollection 2015. Review.

31.

Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.

Gonzalez BD, Jim HS, Donovan KA, Small BJ, Sutton SK, Park J, Lin HY, Spiess PE, Fishman MN, Jacobsen PB.

J Urol. 2015 Sep;194(3):690-5. doi: 10.1016/j.juro.2015.03.026. Epub 2015 Mar 16.

32.

Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma.

Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ.

Clin Genitourin Cancer. 2015 Jun;13(3):225-30. doi: 10.1016/j.clgc.2014.12.001. Epub 2014 Dec 9.

PMID:
25544725
33.

Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Lee M, Jim HS, Fishman M, Zachariah B, Heysek R, Biagioli M, Jacobsen PB.

Psychooncology. 2015 Apr;24(4):472-7. doi: 10.1002/pon.3608. Epub 2014 Jun 13.

34.

Challenges facing the development of cancer vaccines.

Fishman M.

Methods Mol Biol. 2014;1139:543-53. doi: 10.1007/978-1-4939-0345-0_39. Review.

PMID:
24619703
35.

Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.

Brayer J, Fishman M.

J Immunother. 2014 Apr;37(3):187-91. doi: 10.1097/CJI.0000000000000024.

PMID:
24598453
36.

Effects of notch signaling on regulation of myeloid cell differentiation in cancer.

Cheng P, Kumar V, Liu H, Youn JI, Fishman M, Sherman S, Gabrilovich D.

Cancer Res. 2014 Jan 1;74(1):141-52. doi: 10.1158/0008-5472.CAN-13-1686. Epub 2013 Nov 12.

37.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E.

Lancet Oncol. 2013 Nov;14(12):1233-42. doi: 10.1016/S1470-2045(13)70464-9. Epub 2013 Oct 18. Erratum in: Lancet Oncol. 2014 Jun;15(7):e253.

38.

Targeted therapy of kidney cancer: keeping the art around the algorithms.

Fishman MN.

Cancer Control. 2013 Jul;20(3):222-32. Review.

PMID:
23811706
39.

Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.

Larkin J, Fishman M, Wood L, Negrier S, Olivier K, Pyle L, Gorbunova V, Jonasch E, Andrews L, Staehler M.

Am J Clin Oncol. 2014 Aug;37(4):397-403. doi: 10.1097/COC.0b013e31827b45f9.

PMID:
23357974
40.

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.

Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI.

Nat Immunol. 2013 Mar;14(3):211-20. doi: 10.1038/ni.2526. Epub 2013 Jan 27.

41.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
42.

Clinical opportunities in combining immunotherapy with radiation therapy.

Finkelstein SE, Fishman M.

Front Oncol. 2012 Nov 26;2:169. doi: 10.3389/fonc.2012.00169. eCollection 2012.

43.

The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source.

McNab P, Quigley B, Mendoza T, Hakam A, Khalil F, Fishman M, Altiok S.

Int J Clin Exp Pathol. 2012;5(9):982-90. Epub 2012 Oct 20.

44.

Effects of self-directed stress management training and home-based exercise on quality of life in cancer patients receiving chemotherapy: a randomized controlled trial.

Jacobsen PB, Phillips KM, Jim HS, Small BJ, Faul LA, Meade CD, Thompson L, Williams CC Jr, Loftus LS, Fishman M, Wilson RW.

Psychooncology. 2013 Jun;22(6):1229-35. doi: 10.1002/pon.3122. Epub 2012 Jun 20.

PMID:
22715124
45.

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B.

Cancer. 2012 Dec 15;118(24):6152-61. doi: 10.1002/cncr.27632. Epub 2012 Jun 12.

46.

Milestones for development of tivozanib for kidney cancer therapy.

Crescentini R, Gupta S, Fishman M.

Transl Androl Urol. 2012 Jun;1(2):123-5. doi: 10.3978/j.issn.2223-4683.2012.06.08. No abstract available.

47.

Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.

Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M.

Immunotherapy. 2012 Apr;4(4):373-82. doi: 10.2217/imt.12.24.

48.

Cellular immunotherapy for soft tissue sarcomas.

Finkelstein SE, Fishman M, Conley AP, Gabrilovich D, Antonia S, Chiappori A.

Immunotherapy. 2012 Mar;4(3):283-90. doi: 10.2217/imt.12.3. Review.

49.

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

Gupta S, Fishman M.

Expert Opin Pharmacother. 2011 Dec;12(18):2915-22. doi: 10.1517/14656566.2011.636032. Review. Erratum in: Expert Opin Pharmacother. 2012 Feb;13(2):291.

PMID:
22098229
50.

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.

Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC.

Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.

Supplemental Content

Loading ...
Support Center